Concordance Between 21-Gene Recurrence Scores in Multifocal or Multicentric Breast Carcinomas Differs by Age and Histologic Subtype.

Abstract

Among patients with multifocal or multicentric (MF/MC) breast cancer (BC) of similar morphology, concordance in Oncotype DX recurrence scores (RS) between tumors has been reported to be 87%. The effect of age and variation in histologic subtypes on RS concordance according to TAILORx criteria is unknown. We identified patients with MF/MC, estrogen receptor-positive, HER2-negative, node-negative BC with two or more RS results treated at our institution from 2009 to 2018. Patients were analyzed by age group (≤ 50 and > 50years). Low- and high-risk cut-offs were RS ≤ 25 and > 25 for age > 50years, and RS ≤ 20 and > 20 for age ≤ 50years. RS concordance was defined as no change in management based on RS variation between lesions. Overall, 120 patients with MF/MC BC were identified-82 (68.3%) aged > 50years and 38 (31.7%) aged ≤ 50years. Patients aged ≤ 50years had higher mean RS for both multifocal (20 vs. 14; p = 0.006) and multicentric (17 vs. 13; p = 0.003) tumors and more frequently had high-risk tumors (p < 0.0001). Among patients aged > 50years, 95.1% had RS concordance between tumors (same subtype, 98.2%; variable subtype, 88.9%; p = 0.1). Among patients aged ≤ 50years, RS concordance was 81.6%. Among patients with MF/MC BC, RS concordance was high, particularly in those aged > 50years with tumors of the same histologic subtype. RS testing of one focus may be sufficiently prognostic and predictive in patients aged > 50years, regardless of subtype concordance. Testing of individual foci should be considered in patients aged ≤ 50years due to a higher likelihood of RS discordance.